Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: Clinical and pharmacokinetic data

Pancreas

Volumn 32, Issue 1, 2006, Pages 44-50

  Airoldi, Mario ^a   Cattel, Luigi ^b   Passera, Roberto ^b   Pedani, Fulvia ^a   Milla, Paola ^b   Zanon, Claudio ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Gemcitabine; Locally advanced pancreatic adenocarcinoma; Oxaliplatin; Pharmacokinetics; Sequence dependent interaction

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 29144463568     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000191649.47667.06     Document Type: Article

References (21)

1. Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 1997:1126-1161.
2. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985;253:2061-2067.
3. DeCaprio JA, Mayer RJ, Gonin R, et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol. 1991;9:2128-2133.
4. Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997;54:447-472.
5. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
6. Heinemann V. Present and future treatment of pancreatic cancer. Semin Oncol. 2002;29(suppl 9):23-31.
7. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053-1071.
8. Kornmann M, Fakler H, Butzer U, et al. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res. 2000;20:3259-3264.
9. Rougier P, Ducreux M, Kaci MO, et al. Randomized phase II study of oxaliplatin alone (OXA), 5-fluorouracil (5FU) alone, and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarci-noma (APC). Proc Am Soc Clin Oncol. 2000;19:262a.
10. Faivre S, Raymond E, Woynarowski JM, et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 1999;44:117-123.
11. Abbruzzese JL, Frost P. Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and cisplatin. Cancer Chemother Pharmacol. 1992;30:31-36.
12. Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol. 2002;20:1512-1518.
13. Louvet C, Labianca P, Hammel G, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastic pancreatic cancer: results of a GERCOR and GISCAO phase III trial. J Clin Oncol. 2005;23:3509-3516.
14. Alberts SR, Townley PM, Goldberg RM, et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol. 2003;14:580-585.
15. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-3408.
16. Freeman KB, Anliker S, Hamilton M, et al. Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B. 1995;665:171-181.
17. van Warmerdam LJC, van Tellingen O, Maes RAA, et al. Validated method for etermination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fres J Anal Chem. 1995;351:777-781.
18. Mavroudis D, Pappas S, Kouroussis C, et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol. 2003;14:304-312.
19. Faivre S, Le Chevalier T, Monnerat C, et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol. 2002;13:1479-1489.
20. Andrè T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15:1339-1343.
21. Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ tumors cells: a phase II study. Ann Oncol. 2004;15:493-497.